StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

570 Study Matches

Effects of acid sensing ion channels blockade on the exercise pressor reflex following ischemia-reperfusion stress in healthy individuals

The purpose of this voluntary research study is to test if the drug amiloride can decrease blood pressure during exercise.

This project includes 3 visits to the research lab. Each visit last approximately 3.5-4 hours (~11-12 hours altogether). In each visit, you will be asked to perform foot exercise before and after a blood pressure cuff on your leg was inflated. You will also be asked to take pills prior to visit 2 and 3. One of these pills will be a drug called amiloride (10mg), which was traditionally used to lower blood pressure. The other pill will be a placebo (no active medication).

You will receive $25 per hour for your participation in this research study

Yes
 

Jian Cui
Cheryl Blaha - at cblaha@pennstatehealth.psu.edu or 717-531-1605
Heart and Vascular Institute (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00021886
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Men and women of any race or ethnicity
21-40 years of age
Healthy (absence of any active or chronic disease)

Exclusion Criteria:
Are not between 21-40 years old
Pregnant or nursing women
Have a major disease (heart, lungs, kidney, diabetes, cancer)
current smoker
High blood pressure
Heart & Vascular
Prefer not to display
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Young Children’s Representations of Parent-Child Negotiation

The goal of this study is to learn how young children think and tell stories about challenges between parents and children. Children will play games and tell stories using toys while caregivers fill out surveys and talk to researchers. This will occur twice, about 6 months apart. Qualities of children's stories, their language and regulation skills, demographic information about children and caregivers, and parenting behaviors will be examined.

Yes
 

Hannah Mudrick
Hannah Mudrick - at hxm99@psu.edu or 717-948-6404
Behavioral Sciences and Education (HARRISBURG)
 

All
All
This study is also accepting healthy volunteers
STUDY00007452
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Children between the ages of 5 and 7
At least one caregiver of a child between ages 5 and 7
English-speaking
Middle income
Caregiver at least 18 years old

Exclusion Criteria:
Caregivers that are not fluent in English
Children that are not fluent in English
Children who are unable to tell stories with a researcher due to developmental disability or language delay
Children who are younger than 5 or older than 7
Low or high income
Education, Mental & Behavioral Health
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Harrisburg, PA ,

A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open-Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis (PSC).

this is a phase II study to evaluate the safety and tolerability of 2 doses of elafibranor in participants with Primary Sclerosing Cholangitis (PSC), and its potential effect on the change in serum alkaline phosphatase (ALP) and other hepatic markers of PSC during 12 weeks of treatment in the double-blind period (DBP) compared to placebo. This will be followed by a 96-week open-label extension (OLE) period (no placebo) to assess long-term safety and maintenance of effects of elafibranor.After the first dose of the study intervention on Day 1, the participants will have study visits every 4 weeks through Week 12 of the DBP to assess efficacy and safety. In the OLE period, the study visits for each participant will occur after 4 weeks of entering the OLE, then every 12 weeks up to Week 52, followed by every 22 weeks up to Week 96 which will be the end of treatment (EOT). All participants will have a safety follow-up 4 weeks after the last dose of study intervention.

There will be 2 screening visits followed by 4 visits during the double blind/placebo part of the trial, followed by visits every 3 months for the open label part of the study. All visits will be in person. Blood will be drawn at every visit. Urine will be collected at most visits. ECG's (recording of your heart activity) will be done on a regular basis. Additional procedures include fibroscans (scan of your liver to determine liver stiffness) and ultrasound exams of your abdomen and bladder. Multiple questionnaires will be competed throughout the trial period.

Yes
 

Karen Krok
Laurie Peiffer - at lpeiffer@pennstatehealth.psu.edu or 717-531-5226
Medicine: Gastroenterology and Hepatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05627362
STUDY00021989
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of PSC
Elevated ALP

Exclusion Criteria:
Chronic Liver Disease
percutaneous drain or bile duct stent
cholangiocarcinoma
bacterial cholangitis within 60 days
hepatic decompensation
Digestive Systems & Liver Disease
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

The opioid epidemic among Pennsylvania immigrants: Insights from prescribers and rehabilitation professionals

We will interview prescribers and rehabilitation professionals who have provided services and treatment to immigrants in PA with a history of opioid abuse. The goal is to highlight best practices, resources needed, cultural awareness, and training needs to support the rehabilitation and recovery of this client group.

One 45-minute, recorded interview via Zoom

$50.00 Amazon gift card

No
 

Abigail Akande
Abigail Akande - at aoa29@psu.edu
Social and Behavioral Sciences (ABINGTON)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00021288
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Medication Assisted Treatment Provider
Substance abuse treatment provider
Opiate pain medication prescriber
Service provider in PA
Provide services to immigrants (non-citizens)

Exclusion Criteria:
Working outside of PA
No experience with immigrant patients/clients
No experience with opioid use disorder
Addiction & Substance Abuse, Mental & Behavioral Health
Not applicable
I'm interested
Share via email

A randomized, double blind, vehicle-controlled, multicenter Phase II study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) and BF-RhodoLED in the treatment of moderate to severe Acne vulgaris in adults with photodynamic therapy (PDT)

Moderate to Severe Acne Vulgaris: Males/Females 16 years and older. You will receive the study drug with either 1 hour or 3 hours between study drug application and illumination. The purpose of this study is to test the effectiveness and safety of the study drug, used at two different incubation times (time starting with administration of study drug until start of the red light illumination).

Subjects will attend in person visits in the Dermatology Clinical Trial Office. Your length of participation will depend on how your acne responds to the first treatment; the length of participation for 3 treatments will be approximately 25 weeks.Throughout the study at different time points Dr. Zaenglein will evaluate your acne, blood will be drawn, photos will be taken, and questionnaires will need to be completed.

Study Coordinator will discuss during phone screen.

Yes
 

Andrea Zaenglein
Amy Longenecker - at alongenecker@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

All
All
This study is NOT accepting healthy volunteers
NCT05080764
SITE00001055
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 16 years and older may be eligible to participate.
willingness to stop topical facial treatments other than medical cleansers at least 14 days prior to receiving investigational product.
For females must use an adequate and highly effective or two effective methods of contraception throughout the study. Study coordinator will discuss.

Exclusion Criteria:
History of soy or peanut allergy.
For males- beard or other facial hair that might interfere with the study assessments unless subject agrees to be clean-shaven throughout the entire study period.
Certain medications/treatments not allowed during the study; study coordinator will discuss.
Skin Conditions
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Understanding the Media Literacy Competencies of Today’s College Students

This study will involve surveying college students regarding their media literacy competencies and experiences with media literacy education.

No
 

Hans Schmidt
Hans Schmidt - at hcs10@psu.edu or 610-892-1251
Academic Affairs (BRANDYWINE)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00013446
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
College student
18 years of age or older

Exclusion Criteria:
Not 18 years of age or older
Education
I'm interested
Share via email

The perception and experiences of newly diagnosed type 2 diabetes patients (T2D) on the impact of patient-provider communication on subsequent decision to engage in diabetes self-management education (DSME).

This study seeks to explore the perception and experiences of newly diagnosed type 2 diabetes patients about how their interaction with their provider at diagnosis led to their uptake of diabetes education.

No
 

Michelle Boakye
Michelle Boakye - at mdb521@psu.edu or 814-699-1783
Nursing (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00014668
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18 or older
Any gender
Newly diagnosed type 2 diabetes patient within the past 12 months
Have attended at least one diabetes education after diagnosis
Able to provide consent in English

Exclusion Criteria:
Patients who are below 18 years
Patients who have a different type of diabetes either than type 2
Patients diagnosed with Type 2 diabetes more than 12 months
Newly diagnosed diabetes patients who have not attended diabetes self-management education
Diabetes & Hormones
I'm interested
Share via email

Effect of oral black raspberry administration on oral cell DNA adducts in smokers

This is an intervention study that will examine the effect of black raspberry lozenges on mouth cell DNA damage in smokers.

Following one week of being in the study you will be given black raspberry lozenges to take 5 times daily for 8 weeks. Afterwards you will participate in the study for an additional 4 weeks for a ‘wash-out’ period where no lozenges are given. During study visits you will be asked to complete questionnaires, provide a urine sample, and a mouth cell sample by brushing the inside of your cheek with a toothbrush. You will smoke as you normally do throughout the study. You will record cigarette and lozenge use every day. You will complete 2 phone call interviews about your 24-hour food intake during the beginning and the end of the study.

$380

Yes
 

Karam El-Bayoumy
Nicolle Krebs - at nkrebs@pennstatehealth.psu.edu or 717-531-5673
Biochemistry and Molecular Biology (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00013621
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Smokers (5 cigarettes per day or more)
21-75 years of age
No quit attempt in the prior 30 days
No plans to quit smoking in next 4 months
Willingness and ability to attend 8 visits over 13 weeks

Exclusion Criteria:
Current unstable or significant medical condition
Women who are pregnant or nursing
Use of marijuana or other illegal drugs
Any known allergy to raspberries
Heavy drinking (>4 drinks/day, 5 days/wk)
Smoking, Vaping, Nicotine and Tobacco, Food & Nutrition, Prevention
Prefer not to display
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

SNAC Study

This is a multi center clinical trial to test the efficacy of N-acetylcysteine for treatment of patients with active systemic lupus Erythematosus. Healthy control subjects who do not receive treatment are also recruited to serve as controls for the laboratory assays.

This is a clinical trial to be carried out in patients who have systemic lupus erythematosus. Participants will be asked to attend seven study visits over a period of 13 months. After an initial period where it will be determined that the patient can tolerate the medication, N-acetyl cysteine, then there will be a three-month double blind phase where the participant receives either the active treatment or a placebo. At each visit the participant will be asked to complete several questionnaires and blood and urine samples will be obtained. Healthy control individuals will be also enrolled for blood samples only; not for any treatment intervention.

$20 per visit completed

Yes
 

Nancy Olsen
Jamie Carter - at jcarter3@pennstatehealth.psu.edu or 717-531-4921
Medicine: Rheumatology (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
NCT00775476
SITE00001115
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of Systemic Lupus Erythematosus
Age 18 years or older
On stable medications
Experiencing flare of disease

Exclusion Criteria:
pregnant or lactating
regular daily use of Tylenol (acetaminophen)
active chronic infections
current treatment with cyclophosphamide or rituximab
current use of anti-oxidants
Arthritis & Rheumatic Diseases
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Creative Thinking and Problem Solving

This is a behavioral study that will examine cognitive processes relevant for creative thinking. Participants will be asked to complete a series of cognitive tasks and self-report measures on a computer.

Yes
 

Roger Beaty
James Lloyd-Cox - at jll487@psu.edu
Psychology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00010475
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or older
They must consent to participate in research
Healthy volunteers

Native English Speakers

Exclusion Criteria:
Cannot be non-native English speakers
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Investigating the impact of food form on children’s ability to compensate for energy

This study is looking at how different apple products (apple juice, apple sauce, and apple slices) might affect children's hunger and fullness. During 5 visits to our laboratory at Penn State, children will participate in a variety of games and tasks, and will eat meals and snacks with a research assistant. Children must be between the ages of 4.5-6 years old to participate in this study.

There will be 5 in-person visits. During each visit, children will consume an apple-based snack (apple slices, apple sauce, or apple juice) before a meal. Children will also wear a small heart rate monitor during each visit. On each visit, different games and tasks will be completed with the children while the parent completes various surveys.

$200-400

Yes
 

Kathleen Keller
Benjamin Baney - at bab349@psu.edu or 814-883-8523
Nutritional Sciences (UNIVERSITY PARK)
 

All
Younger than 18 years old
This study is also accepting healthy volunteers
STUDY00013957
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Between age of 4.5-6.0 years-old
No food allergies

Exclusion Criteria:
Taking medication that can affect taste or appetite
Children's Health, Food & Nutrition
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Angelica Herbal Supplement AGN-Cognl.Q Acute Dose Safety and Pharmacokinetics (PK) Dose-Response in Prostate Cancer Patients (PK Dose Trial)

The primary objective is to estimate the maximum tolerated dose of AGN-Cognl.Q. Subjects (total sample size n = 12 evaluable subjects), each for 4 ascending AGN-Cognl.Q dose levels in the form of AGN-Cognl.Q capsules (up to 10 capsules per dose), for single-dose safety metrics with a 1-week washout between doses.

Consented patients will be screened for physical exam and lab tests, and vital signs to establish eligibility (Visit 1, screening visit). The subjects will need to come into the research clinic in Hershey Medical Center on a weekly basis to take a single dose of AGN-CognI.Q by mouth in the morning for a series of blood draw over the span of the next 24 h to measure the amount of AGN Cognl.Q in their body. The total number of times the subjects will visit the clinic is 8 including a Screening visit (Visit 1) and an End of Treatment visit (Visit 8).

Yes
 

Monika Joshi
Kathleen Rizzo - at krizzo@pennstatehealth.psu.edu
Medicine: Hematology and Medical Oncology (HERSHEY)
 

Male
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05375539
STUDY00020512
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Willingness and ability to given informed consent
agree to comply with all study procedures and attend all study visits to the best of their ability
male with age >= 40 years
Histologically confirmed prostate cancer diagnosis in the past
Not on concurrent androgen deprivation therapy

Exclusion Criteria:
Subjects with metastatic cancer as determined by chest and abdominal CT scan, PET/CT, MRI, bone scan within the past 12 months
Subjects who are receiving chemotherapy, or oral TKI, or immunotherapy
Subjects who are receiving any other investigational agents
Uncontrolled intercurrent illness that would limit compliance with study requirements
Subjects currently taking herbal supplements containing AGN extract, including Cognl.Q, Decursinol-50, Ache Action, Fast-Acting Joint Formula, EstroG-100/Profemin
Cancer
Approved drug(s)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

My Character is...Myself? Exploring Attachment Styles, View of Self, Virtual Self-Discrepancy, & Character Attachment

The goal of this research is to confirm the relationships between virtual self-discrepancy, character attachment, view of self, attachment styles, and the potential for a moderating variable within the relationships as a starting point for future research tying in player/character relationship and gaming addiction.

No
 

Jessica Smith
Jessica Cornelius Smith - at jjc6618@psu.edu or 870-403-7817
Behavioral Sciences and Education (HARRISBURG)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00016362
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be 18 years of age or older.
Players that engage in role-play gaming using a character they have spent a significant amount of time creating.
Participants that can understand English

Exclusion Criteria:
Participants younger than 18 years of age.
Players that do not engage in role-play gaming using a character they have spent a significant amount of time creating.
People who do not speak and read English.
Mental & Behavioral Health
I'm interested
Share via email

A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML)(M19-063)

This study is to determine the recommended Phase 3 dose of venetoclax in combination with azacitidine in Acute Myeloid Leukemia patients when given as maintenance therapy following allogeneic stem cell transplantation. It also is to determine if venetoclax can be effective in combination with azacitidine to improve Relapse Free Survival in Acute Myeloid Leukemia patients compared to Best Supportive Care (BSC) when given as maintenance therapy following allogeneic stem cell transplantation.

There are different phases of this study. The first phase is Screening, then there is the Treatment phase as well as a Follow up phase. Each phase will have testing and procedures that will require you to come to the study center.

50.00 Travel expenses

Yes
 

Shin Mineishi
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04161885
STUDY00015638
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adult male or female ≥ 18 years old; and, for Part 2 only, male or female at least 12 years old.
Subject must be diagnosed with Acute Myeloid Leukemia by World Health Organization (WHO) criteria (2017) and either be planning for allogeneic stem cell transplantation or have received allogeneic transplantation within the past 14 days.
Subjects that have previously been treated with venetoclax, can only be included if there was no history of disease progression during venetoclax treatment.
Grafts must be from one of the following sources: Bone marrow or peripheral blood stem cells or cord blood cells irrespective of degree of matching.
Subjects and/or their legally authorized representative (where permitted per local regulations) must voluntarily sign and date an informed consent form (and assent form for minors if required by applicable regulations)

Exclusion Criteria:
No malabsorption syndrome or other condition that precludes oral route of administration.
No history of any other malignancy within 2 years prior to study entry
Subject has no known evidence indicating leukemia relapse, which may include immunophenotype, cytogenetic or molecular methods.
No psychiatric illness/social situation that would limit compliance with the study.
No evidence of other clinically significant uncontrolled systemic infection.
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Phase 2 Study of Bladder-SparIng ChemoradiatioN with Durvalumab (PSCI# 19-072) (EA8185)

The purpose of this study is to compare the usual treatment of chemotherapy and radiation to adding MEDI4736 (durvalumab) immunotherapy to the usual treatment. The addition of MEDI4736 (durvalumab) immunotherapy to the usual treatment may help shrink your cancer better than the current standard of care or usual approach for bladder cancer. But, it could also cause side effects, which are described in the risks section.This study will help determine if this different approach is better than the usual approach. To decide if it is better, the study doctors will be looking to see if the study approach increases the life of patients by 6 months or more compared to the usual approach.

If you decide to take part in this study, you will either get chemotherapy and radiation for 6-8 weeks, or you will get durvalumab immunotherapy in addition to chemotherapy and radiation for 6.5-8 weeks. After you finish your study treatment, your doctor will continue to follow you for up to 3 years. The follow-up will consist of visits to his or her office and CT scans of the bladder.

Yes
 

Monika Joshi
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04216290
SITE00000823
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patient must have an ECOG Performance Status of 0-2 at the time of registration.
Patient must have histologically proven pure or mixed urothelial cancer of the bladder.
Patient must be ≥ 18 years of age.
Must have adequate renal function as evidenced by calculated (Cockcroft’s formula) creatinine clearance or 24 hours actual creatinine clearance ≥ 30mL/min.
Patient must have a life expectancy of at least 12 weeks, as determined by the treating physician.

Exclusion Criteria:
Patients with clinical N3 disease are ineligible.
Patient must not have received any previous radiation therapy to the pelvic area.
Women must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.
Patients with a negative biopsy of nodes determined to be suspicious on imaging are not eligible.
Small cell carcinoma is excluded, however other variant histologies are permitted provided a component of urothelial carcinoma is present.
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Mental wellbeing during the Covid-19 pandemic: a study of essential workers and social media use

Through in-depth interviews, we examine how the Covid-19 pandemic has impacted the daily lives and mental well-being of essential workers, as well as their use of social media.

No
 

Saeed Abdullah
Johnna Blair - at jlb883@psu.edu
Information Sciences and Technology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00015851
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Considered an “essential worker”---working outside of their homes during the Covid-19 pandemic (e.g. front line medical professionals, paramedics, hospital workers, grocery store employees, delivery drivers, factory workers, etc.)
Social media users (e.g. Twitter, Instagram, Facebook)
Adults 18 or older
Social media users

Exclusion Criteria:
Considered "non-essential" workers during the Covid-19 pandemic
those working from home during the Covid-19 pandemic
minors (those under 18)
those who do NOT use social media
Men's Health, Mental & Behavioral Health, Women's Health
I'm interested
Share via email

Hand Action and Perception in Parkinson's Disease

The purpose of this research study is 1.) to determine if Parkinson’s Disease (PD) causes changes in the way that people sense the movements of and forces produced by their bodies, and to connect any of these changes in sensation to changes in the brain, and 2.) to identify how changes in movement might come from different parts of the nervous system. This study will use a combination of electromyography, via electrodes placed on the skin, and finger force recordings to infer how PD affects patients' sense of force production, and the neural mechanisms underlying this change.

This study requires a single in-person visit. We will use adhesive skin sensors on the forearms to measure muscle activity. At the same time, we test the participant's finger strength and then ask them to press with moderate force on piano-key-like sensors. Participants will be asked to match force levels between hands and to move an on-screen cursor into a target.

$40.00

Yes
 

Janina Prado Rico
Janina Prado-Rico - at jpradorico@pennstatehealth.psu.edu
Neurology (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00020063
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Persons diagnised with Parkinson's disease or Essential Tremor, age 40-85, or subjects without Parkinson's disease, age 21-85
No history of earning disability, neurodevelopmental disorder, seizures, multiple concussion (> 3), cerebrovascular disease, brain tumor, hydrocephalus, or any CNS disease other than PD.
No present carpal tunnel syndrome, cervical myelopathy, brachial plexopathy, hand pain, or another neuromusculoskeletal disorder affecting hand function
No history of alcohol and/or drug abuse.

Exclusion Criteria:
History of specialized hand training such as professional musicianship.
Neurology
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

GPRPL Study

The purpose of this study is to find genetic causes of recurrent pregnancy loss (RPL). RPL is defined by two or more miscarriages under 20 weeks gestation and affects approximately 5% of women.The causes of RPL are not well understood. After all the currently recommended testing for RPL has been done, about half of women with RPL will still have no identifiable cause. This lack of knowledge makes it difficult to provide effective medical care for couples with RPL.This study will compare reading about 20000 genes in the entire human genetic library by whole genome sequencing in the miscarriage material and also your and your partner’s DNA from blood samples. The DNA in a person is a combination of the DNA from each of their biological parents. If you have healthy children we may ask your consent for them to give a blood sample for DNA extraction and testing. Similarly, we may ask the same for other family members such as grandparents if necessary. We may also request your permission to use stored DNA or miscarriage material from previous pregnancy loss if available. Testing of family members or previous miscarriage materials may help to understand DNA sequence variants or changes identified in the miscarriage sample.

There will be a one time collection of blood samples.

Yes
 

Sarah Horvath
OBGYNResearch@pennstatehealth.psu.edu
Obstetrics and Gynecology (HERSHEY)
 

Female
18 year(s) or older
This study is also accepting healthy volunteers
SITE00001050
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Women with current pregnancy loss
Two or more prior losses of clinically recognized pregnancies
Prior losses are unexplained

Exclusion Criteria:
Known cause for pregnancy loss and/or prior losses
Pregnancy & Infertility
Prefer not to display
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Voice Perception Study

This is a voice perception study that asks participants to listen to voices and rate on various attributes such as attractiveness, social status, health, and others.

No
 

Toe Aung
Toe Aung - at txa96@psu.edu or 775-225-1747
Anthropology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00009763
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18-40
Gender/Sex: Men/Male; Women/Female
Education: PSU students and participants recruited online

Exclusion Criteria:
Uncorrected severe defects of hearing
Participants who already completed the survey
Participants who took the survey on the mobile phone
Men's Health, Women's Health
I'm interested
Share via email

Age Comparisons of Exercising Muscle O2 Supply in Healthy Adults: Effects of Esmolol Infusion

This research is being conducted to determine how oxygen extraction within exercising muscles is altered in younger and older women when beta-1 receptors (receptors that contribute to the rise in heart rate with exercise) are temporarily blocked through a medication infused into an arm vein. The findings will help us understand how aging affects the regulation of oxygen supply to working muscles is regulated with normal aging.

There will be 3 in person visits.Visit 1) Subjects will undergo a physical and one blood draw in the Clinical Research Center and then perform two recumbent cycling exercise trials on a stationary bike.Visit 2) Subjects will undergo a DXA scan and then perform two recumbent cycling exercise trials.Visit 3) Subjects will have an IV catheter inserted into an arm vein. They will then perform two recumbent cycling exercise trials. During one trial the will receive esmolol via the IV catheter and during the other they will receive saline via the IV catheter (random order).

$150

Yes
 

David Proctor
Matthew Studinski - at mxs1455@psu.edu or 715-498-8093
Kinesiology (UNIVERSITY PARK)
 

Female
18 year(s) or older
This study is also accepting healthy volunteers
NCT04181606
STUDY00010736
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Premenopausal women (18-35 years)
Postmenopausal women (55-70 years)

Exclusion Criteria:
Users of any tobacco and/or nicotine products
Individuals taking hormone therapy
Pregnant or lactating
Individuals with any over cardiovascular, metabolic, hematologic, pulmonary, renal, musculoskeletal, and/or neurological disorders
Heart & Vascular
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Phase II Trial of Palbociclib with Fulvestrant in Individuals withHormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer who have Progressed on Treatment with Palbociclib and an Aromatase Inhibitor

In this phase II trial, we will determine the progression-free survival (PFS) of the cyclin dependent kinase 4/6 inhibitor (CDK4/6i) palbociclib with fulvestrant in women and men with estrogen or progesterone receptor (ER/PR) positive, HER2-negative metastatic breast cancer (MBC) who progressed on treatment with palbociclib and an aromatase inhibitor (AI). We will also determine the prevalence rate of estrogen eceptor α (ESR1) and phosphatidylinositol-3-kinase (PI3K) mutations in the study population.

Participants will be required to come to the clinic every three weeks for evaluation and fulvestrant injections, take medication correctly, keep all appointments.

Yes
 

Cristina Truica
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02738866
STUDY00010878
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Men and women, 18 years of age or older
Histologically or cytologically confirmed adenocarcinoma of the breast with evidence of metastatic disease (stage IV) or locally advanced disease,
ER-positive and/or PR-positive tumor (≥1% positive stained cells) • HER2-negative tumor
Progressed on and following at least 6 months of combined treatment with palbociclib and AI therapy for advanced/metastatic breast cancer, and be able and willing to receive additional palbociclib treatment
Eastern Cooperative Oncology Group (ECOG) performance status 0-2

Exclusion Criteria:
Women who are pregnant or breast-feeding
Concurrent use of any of the following medications during study participation: • Inhibitors or inducers of CYP3A4 that may affect serum concentrations of palbociclib
Major surgery, chemotherapy, radiotherapy, or other anti-cancer therapy within 2 weeks before registration.
Any other malignancy within 3 years prior to registration, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.
Prior hematopoietic stem cell or bone marrow transplantation.
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Depressive Symptomatology and Inflammation

The purpose of this research is to investigate the associations between depressive symptoms and inflammation. The researchers are studying how specific symptoms of depression (such as fatigue, sadness, impaired concentration, and loss of pleasure) are related to markers of inflammation, which is a key component of our immune system. Volunteers with depressive symptoms, as well as volunteers without depressive symptoms are needed for this research study. This study includes an online survey to determine eligibility and one in-lab visit. Participants who are eligible will be scheduled for one in-lab visit (2.5-3h for participants with depressive symptoms & 1-2h for participants without depressive symptoms), where they will be asked to answer surveys with questions related to depressive symptoms and complete a number of tasks (using an iPad and a touch screen phone) that measure thinking skills including attention, memory and reaction time. Participants will also undergo a single blood draw to assess inflammatory markers.

Participation will require one in person visit at the CRC that takes from 1 to 1.5 hours total where they will have their blood drawn, fill out surveys about their mood, and complete cognitive tests.

30

Yes
 

Molly Wright
Molly Wright - at mpw5810@psu.edu
Division of Graduate Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00011171
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Fluent in English
No history of depression
Free of chronic inflammatory or autoimmune disorders
If female, not pregnant or nursing

Exclusion Criteria:
Personal or family history (first-degree relatives) of major depressive disorder or major psychiatric illness
Taking non-steroidal anti-inflammatory agents or statins everyday within the past month
Taking antipsychotics or mood stabilizers
If female, are post-menopausal or pregnancy/lactation
Infectious Diseases & Immune System, Mental & Behavioral Health
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Asymmetries in Cognitive Aspects of Motor Control and Learning

This study will improve our understanding of movement control and how strokes of different sides affect overall independence. Participants will complete the visit seated at a chair with sensors connected to the less-affected arm. They will then play a short virtual reality game and complete several questionnaires and assessments.

Yes
 

Robert Sainburg
Shanie Jayasinghe - at sjayasinghe@pennstatehealth.psu.edu or 717-531-0003, ext=283146
Kinesiology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00015871
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Right handed (pre-stroke)
Neurological confirmation of unilateral stroke
Severe paresis on one side only
Adults over the age of 18
Chronic stage of stroke (>3 months post stroke)

Exclusion Criteria:
Left-handed (pre-stroke)
Neuro radiological confirmation of extensive periventricular white matter changes
History of neurological diseases other than stroke
Significant joint pain that is activity limiting
Neurology
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Personalized assessment of daily experiences

The purpose of this voluntary research study is to understand how experiences that might change moment-to-moment influence suicidal thoughts and behaviors for individual people. In other words, the purpose of this research is to understand how much the experiences that lead to suicidal thoughts and behaviors might differ from person to person. This research includes people living in rural areas of the United States because people living in rural areas are not often represented in suicide research, even though suicidal thoughts and behaviors are important issues for people in rural communities. We want to make sure that we understand how suicidal thoughts and behaviors might develop specifically for individual people living in rural areas. We also want to understand how suicidal thoughts and behaviors develop specifically for LGBTQIA+ people who live in rural areas.

First, you will complete surveys at a baseline assessment. Second, following the baseline assessment, you will be asked to complete short assessments of your mood, thoughts, and behaviors, 5 times per day for 21 days. Each assessment should take less than 2 minutes to complete. Third, at the end of the 21-day period, you will provide feedback on your experience rating your mood, thoughts, and behaviors. Fourth, you will complete 12 brief weekly assessments. Fifth, you will complete surveys four months after completing the baseline assessment.

$300

No
 

Lauren Forrest
Sarah Hauryski - at shauryski@pennstatehealth.psu.edu
Psychiatry and Behavioral Health (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00020173
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
age 18-64
own a smartphone with internet and email access
English language fluency
Lifetime suicide attempt with past-year suicidal ideation or a suicide plan or suicide intent within the last 12 months
Live in a rural area of the United States

Exclusion Criteria:
cognitive impairment
mania
psychosis
Mental & Behavioral Health
Not applicable
I'm interested
Share via email

The Use of Micro-Doppler Radar to Identify Service Members at Risk for Musculoskeletal Injury: A Gold Standard Comparison

The purpose of this research study is to see if we can use micro-doppler signal technology to determine if someone has had an ACL reconstruction in the past. We will do this by comparing a group of people who have had the surgery against a group who has never had this surgery to see if this technology can tell the difference.

If you join this study you would be asked to come to a one-hour appointment at the Lebanon Valley College campus in Annville, PA and perform a variety of activities that are part of daily life, such as walking, jumping, and standing from a seated position. We'll ask you to complete a questionnaire on any musculoskeletal pain you're experiencing and report your demographic information.

50

Yes
 

Cayce Onks
Leonard Kishel - at lkishel@pennstatehealth.psu.edu or 717-531-0003, ext=321657
Family and Community Medicine (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00020118
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 18-40
ACL Group: ACL Reconstruction surgery 9-72 months prior and approved to return to normal activities
Control group: No history of lower extremity surgery
Able to provide consent and read/write in English
No current musculoskeletal injuries

Exclusion Criteria:
Prisoner
Pregnant person
any surgery within 6 months of the study visit
Unable to provide consent or read/write in English
Unable to perform movements consistent with daily activities such as walking, jumping, or moving from sit to stand
Prevention, Sports Medicine, Muscle & Bone
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Human Interaction with Information and Communication Technology

This study investigates users’ experience with Information and Communication Technology (ICTs). This study makes further implications for designing more user-friendly ICT for a better user experience. We aim to make such contributions by answering these questions:1.How do users interact with ICTs?2.What challenges do users face when using ICTs?3.What strategies do users apply to adapt themselves to ICTs?4.What service do ICT producers provide for users to get better user experience?5.When does user experience break down when interacting with ICTs?

No
 

Yao Lyu
Yao Lyu - at yml5549@psu.edu
Information Sciences and Technology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00016978
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or elder
all genders included
have prior experience with ICT
speak Madarin or English

Exclusion Criteria:
younger than 18 years old
vulnerable populations like cognitive impaired adults, prisoners.
no prior experience with ICT
speak neither Madarin nor English
I'm interested
Share via email

Watch Over: Using Apple Watches to Assess and Predict Substance Co-use in Young Adults

This study seeks to understand substance use and other health behaviors in young adults' daily lives. Interested participants can email the study team to complete a brief screener to see determine their eligibility. If eligible, participants will be asked to complete a short online survey and follow-up surveys for up to four weeks via a mobile device. Financial compensation will be provided.

This study involves three parts. First, potential participants will complete an online screener survey. If they are eligible, they will be immediately enrolled in the study and will proceed to the baseline survey. Second, participants who have completed the baseline portion of the study will schedule an in-person visit with the research team for the next portion of the study. At the start of the in-person visit, participants will be oriented about the study design which involves completing daily surveys about various health behaviors. Third, participants will come back in-person for a brief final visit and receive payment.

76

Yes
 

Ashley Linden-Carmichael
Sahiti Kunchay - at sahiti@psu.edu
Methodology Center (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00013672
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Between 18-25 years of age
Current Penn State student
Currently owns and uses an iPhone with iOS version 15 or newer
Determined eligible through screener

Exclusion Criteria:
Eligibility determined using a screening survey
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

EA8183 A Phase III Study of Early Intervention after RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE) (PSCI# 21-122)

This study is being done to answer the following question:Will the addition of a new drug, darolutamide, to standard Androgen Deprivation Therapy (ADT) (a hormonal therapy that is a usual approach to treatment) after surgery cure more men with prostate cancer than using Androgen Deprivation Therapy alone?We are doing this study because we want to find out if this approach is better or worse than the usual approach for your prostate cancer. The usual approach is defined as care most people get for prostate cancer.

This study is being done to answer the following question:Will the addition of a new drug, darolutamide, to standard Androgen Deprivation Therapy (ADT) (a hormonal therapy that is a usual approach to treatment) after surgery cure more men with prostate cancer than using Androgen Deprivation Therapy alone?We are doing this study because we want to find out if this approach is better or worse than the usual approach for your prostate cancer. The usual approach is defined as care most people get for prostate cancer.

Yes
 

Joseph Miccio
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Radiation Oncology (HERSHEY)
 

Male
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04484818
SITE00001026
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patient must be = 18 years of age.
Patient must have undergone a radical prostatectomy (RP) and must be preregistered to Step 0 of this study at least 6 weeks after but not more than 12 weeks after their radical prostatectomy.
Patient must not have any previous treatment with androgen deprivation therapy (ADT), chemotherapy, or other physician prescribed systemic therapy for treatment of their prostate cancer.
Patient must have an ECOG performance status of 0-2.

Exclusion Criteria:
Patient must not have pathologic evidence of pelvic lymph node involvement.
Patient must not have an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III and IV heart failure).
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Biologic and Environmental Impacts on Neurodevelopment and Growth (BEING)

Examine associations between biologic factors (genetic, epigenetic, transcriptomic, metabolomic) and environmental factors (family psychosocial dynamics, environmental allergens, diet, microbiome) in developing children, and their relationship with health and disease over the lifespan.

Depending on the age your child is when they are enrolled into the study will determine their designated enrollment group (Cohort 1, Cohort 2, Cohort 3, or Cohort 4) to determine how many study visits are required to complete participation in the study.For Cohort 1 participants (for infants enrolled at age 5-50 days):-11 study visits total -Each study visit includes surveys that assess your child's growth and development that you can complete via your email-Each study visit includes at minimum a saliva swab sample**Infants will be asked to collect a stool sample for 3 study visits-Optional mother participant for breast-feeding mothers who will agree to provide a small breast milk sample for 3 study visits.For Cohort 2 participants (for children enrolled at age ~24 months):-8 study visits total -Each study visit includes surveys that assess your child's growth and development that you can complete via your email-Each study visit includes a saliva swab sample**Children will be asked to collect a stool sample for 1 study visitFor Cohort 3 participants (for children enrolled at age 5-7 years):-5 study visits total -Each study visit includes surveys that assess your child's growth and development that you can complete via your email-Each study visit includes a saliva swab sampleFor Cohort 4 participants (for children enrolled at age 12-14 years):-2 study visits total -Each study visit includes surveys that assess your child's growth and development that you can complete via your email-Each study visit includes a saliva swab sample

30-100

No
 

Steven Hicks
Alexandra Confair - at aconfair1@pennstatehealth.psu.edu or 717-531-0003, ext=323206
Pediatrics: General Pediatrics (HERSHEY)
 

All
Younger than 18 years old
This study is also accepting healthy volunteers
STUDY00014022
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Child participant under 18 years old
Fluent in spoken/written English
Parent or legal guardian 18+ years old
Child ages: 5-50 days old, 2 years old, 5-7 years old, and 12-14 years old

Exclusion Criteria:
Wards of the state
Non-english speaking
Parent or legal guardian with decisional impairment
Children's Health
I'm interested
Share via email

Parent-to-child anxiety transmission in early childhood: Capturing in-the-moment mechanisms through emotion modeling and biological synchrony

Anxiety can emerge as early as pre-school age (4-7) and is often linked to anxiety in the parent. This study will examine patterns of brain and behavioral synchrony in parent-child pairs as they complete puzzles together and other social activities.

Participation requires three steps; a remote video session with the primary parent, an in-lab visit scheduled with the primary parent and child, and then an additional set of questionnaires given to the secondary caregiver.The remote session consists of obtaining consent, 2 questionnaires, and a clinical interview. The in-lab visit typically lasts about 2-3 hours, consisting of two parent-child activities and several child-only activities. Participants will be asked to wear mobile eye-tracking glasses and special caps used to measures brain activity during some of the tasks.

$125, $100 for the primary parent/or child and $25 for secondary parent

Yes
 

Koraly Perez-Edgar
Dakota Reis - at drr5484@psu.edu or 814-867-2322
Psychology (UNIVERSITY PARK)
 

All
All
This study is also accepting healthy volunteers
STUDY00017857
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Parents/Caregivers over 18
Children ages 4 to 6

Exclusion Criteria:
major medical illness
Children less than age 4 or over age 6
Children's Health, Mental & Behavioral Health
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,